These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2276119)

  • 1. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.
    Cedarbaum JM; Léger G; Reches A; Guttman M
    Clin Neuropharmacol; 1990 Dec; 13(6):544-52. PubMed ID: 2276119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.
    Cedarbaum JM; Leger G; Guttman M
    Clin Neuropharmacol; 1991 Aug; 14(4):330-42. PubMed ID: 1913700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
    Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
    Keränen T; Gordin A; Harjola VP; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Seppälä L; Wikberg T
    Clin Neuropharmacol; 1993 Apr; 16(2):145-56. PubMed ID: 8477410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
    Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
    Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
    Ahtila S; Kaakkola S; Gordin A; Korpela K; Heinävaara S; Karlsson M; Wikberg T; Tuomainen P; Männistö PT
    Clin Neuropharmacol; 1995 Feb; 18(1):46-57. PubMed ID: 8665534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
    Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
    Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice.
    Törnwall M; Tuomainen P; Männistö PT
    Arch Int Pharmacodyn Ther; 1992; 320():5-20. PubMed ID: 1300941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
    Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
    Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.
    Almeida L; Vaz-da-Silva M; Silveira P; Falcão A; Maia J; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
    Clin Neuropharmacol; 2004; 27(1):17-24. PubMed ID: 15090932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.
    Nissinen E; Lindén IB; Schultz E; Kaakkola S; Männistö PT; Pohto P
    Eur J Pharmacol; 1988 Aug; 153(2-3):263-9. PubMed ID: 3181288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
    LeWitt P; Liang GS; Olanow CW; Kieburtz KD; Jimenez R; Olson K; Klepitskaya O; Loewen G
    Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):43-50. PubMed ID: 36688497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
    Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
    Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S; Gordin A; Männistö PT
    Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
    Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
    Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of nitecapone and clorgyline, given intracerebro-ventricularly on L-dopa metabolism in the rat brain.
    Männistö PT; Törnwall M; Tuomainen P; Borisenko SA; Tuominen RK
    Neuroreport; 1992 Jul; 3(7):641-4. PubMed ID: 1421124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.
    Yamamoto J; Omura T; Kasamo S; Yamamoto S; Kawata M; Yonezawa A; Taruno Y; Endo H; Aizawa H; Sawamoto N; Matsubara K; Takahashi R; Tasaki Y
    J Neural Transm (Vienna); 2021 Jan; 128(1):27-36. PubMed ID: 33136226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.